Andere Kunden interessierten sich auch für
![Formulierung und Bewertung von Mosaprid-Matrix-Tabletten mit verzögerter Freisetzung]( "Formulierung und Bewertung von Mosaprid-Matrix-Tabletten mit verzögerter Freisetzung")
Formulierung und Bewertung von Mosaprid-Matrix-Tabletten mit verzögerter Freisetzung43,90 €![Sustained Release Matrix Tablet of Cefuroxime Axetil]( "Sustained Release Matrix Tablet of Cefuroxime Axetil")
Sustained Release Matrix Tablet of Cefuroxime Axetil32,99 €![Designing of Sustained Release Matrix Tablet of Antidiabetic Drug]( "Designing of Sustained Release Matrix Tablet of Antidiabetic Drug")
Designing of Sustained Release Matrix Tablet of Antidiabetic Drug32,99 €![Development of Sustained Release Matrix Tablets of Lansoprazole]( "Development of Sustained Release Matrix Tablets of Lansoprazole")
Development of Sustained Release Matrix Tablets of Lansoprazole23,99 €![Pinaverium sustained release matrix tablets for colonic drug delivery]( "Pinaverium sustained release matrix tablets for colonic drug delivery")
Pinaverium sustained release matrix tablets for colonic drug delivery26,99 €![Matrix Tablets: An Approach Towards Sustained Release Drug Delivery]( "Matrix Tablets: An Approach Towards Sustained Release Drug Delivery")
Matrix Tablets: An Approach Towards Sustained Release Drug Delivery36,99 €![The formulation and evaluation of the sustained release matrix tablets]( "The formulation and evaluation of the sustained release matrix tablets")
The formulation and evaluation of the sustained release matrix tablets26,99 €
The present study was carried out to develop sustained release matrix tablets of mosapride citrate dihydrate. Matrix tablets of mosapride citrate dihydrate with two different viscosity grades of hydroxypropyl methylcellulose were prepared by dry granulation and direct compression method and evaluated.The study demonstrated that combination of HPMC K4M and HPMC mosapride citrate dihydrate. This can be expected to reduce the frequency of administration and decrease the dose - dependent side effects associated with repeated administration of conventional mosapride citrate dihydrate tablets. The cumulative drug release of innovators brand (MOZA SR, Intas Pharmaceuticals) of sustained release tablet of mosapride citrate dihydrate were compaired for in vitro dissolution study.Hence it can be concluded that once daily sustain release matrix tablet of mosapride citrate dihydrate having short half life, was found to exert a satisfactory sustained release profile which may provide an improved bioavailability, increased therapeutic efficacy and patient compliance.